Immunosuppressants in dermatology on vaccine immunogenicity: a prospective cohort study of pemphigus patients in the pandemic
Except for a subset of patients with unrecovered B-cell deficiency, rituximab infusion with proper scheduling of vaccination preserved better anti-viral T-cell responses and did not lead to hindered antibody responses in pemphigus patients. All pemphigus patients benefited from receiving the third booster regardless of B-cell status.
Authors
- Chuang‐Wei Wang (ORCID: https://orcid.org/0000-0002-7921-4129)
- Rosaline Chung‐Yee Hui (ORCID: https://orcid.org/0000-0001-8262-2556)
- Chun‐Wei Lu (ORCID: https://orcid.org/0000-0002-6872-4764)
- Ya‐Ching Chang (ORCID: https://orcid.org/0000-0003-4937-7557)
- Chun‐Bing Chen (ORCID: https://orcid.org/0000-0002-7378-4235)
- Kun‐Lin Lu (ORCID: https://orcid.org/0000-0002-2647-2597)
- Wen‐Hung Chung (ORCID: https://orcid.org/0000-0003-1681-0959)
- Hua-En Lee
Institutions
- Chang Gung University (TW)
- Shanghai Jiao Tong University (CN)
- National Tsing Hua University (TW)
- Ruijin Hospital (CN)
- Chang Gung Memorial Hospital (TW)
- Keelung Chang Gung Memorial Hospital (TW)
- Xiamen Chang Gung Hospital (CN)
- Beijing Tsinghua Chang Gung Hospital (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-22
- DOI
- https://doi.org/10.3389/fimmu.2024.1506962
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chang Gung Medical Foundation
- Ministry of Science and Technology, Taiwan
- Chang Gung Memorial Hospital, Linkou